CompletedPHASE1, PHASE2NCT01838655

Nitisinone for Type 1B Oculocutaneous Albinism

Studying Oculocutaneous albinism type 5

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Eye Institute (NEI)
Principal Investigator: Brian P Brooks, M.D.
National Eye Institute (NEI)
Intervention: Nitisinone(drug)
Enrollment: 5 enrolled
Eligibility: 18 years · All sexes
Timeline: 2013 – 2017

Study locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Collaborators

National Human Genome Research Institute (NHGRI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01838655 on ClinicalTrials.gov

← Back to all trials